Eli Lilly has followed Novo Nordisk in announcing ... and dual GIP/GLP-1 agonist Mounjaro (tirzepatide) for diabetes, as well as newly-approved obesity therapy Zepbound (tirzepatide).

Eli Lilly & Co. said Thursday that its Type 2 diabetes drug Mounjaro and its weight-loss and diabetes drug Zepbound drove a 45% increase in fourth-quarter revenue to $13.53 billion. The drugmaker ...

The lesser celandine, also known as fig buttercup, is a low-growing perennial plant found in moist floodplains during the ...

Why Are Anthurium Plants Popular? The exotic-looking heart-shaped “blooms” that make anthurium irresistible as houseplants are, in fact, spathes, or modified leaves surrounding the spadix, a stem ...

One of the highlights of Eli Lilly's third-quarter results was the rapid uptake of new type 2 diabetes therapy Mounjaro, which added more than $97 million in US sales alone in what has been ...

Sales of Lilly’s top-selling product, the diabetes treatment Mounjaro, jumped 60% to $3.53 billion in the final quarter of 2024 while its obesity treatment counterpart Zepbound brought in $1.9 ...

Lilly's growth was led by its GLP-1 drugs. For the quarter, revenue for Mounjaro soared 60% year over year to $3.5 billion, while revenue for Zepbound surged from $175.8 million to $1.9 billion.

The recent surge has been due to the tremendous growth Lilly has achieved due to its highly popular GLP-1 drugs, including Mounjaro (for diabetes) and Zepbound (for weight loss). Together ...

On the top-line, Lilly’s revenue grew by 45%, a brisk pace that was in line with expectations. Earnings more than doubled, beating analyst estimates by 6%. Mounjaro and Zepbound, the company’s ...